Research Advances and Clinical Impact of New Data From Crohn’s & Colitis Congress® 2019

February 7-9, 2019; Las Vegas, Nevada
Review expert commentary of key data from the 2019 Crohn’s and Colitis Congress
Baldeep S. Pabla, MD, MSCI
D. Brent Polk, MD, AGAF
David A. Schwartz, MD, FACG, AGAF


How might IBD disease activity and drug monitoring affect our approach to treatment? Here’s my take.

D. Brent Polk, MD, AGAF Released: June 7, 2019

We highlight our thoughts on the most recent data for 3 new and emerging IBD treatments.

Baldeep S. Pabla, MD, MSCI David A. Schwartz, MD, FACG, AGAF Released: June 26, 2019
Produced in collaboration with
Supported by educational grants from
Takeda Pharmaceuticals USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?